Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCS.
Page 3: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
601 | 6 | 12 | 1148 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):227-228 Allen BR Thalidomide | 4 | 4 |
602 | 4 | 4 | 1150 2001 BRITISH JOURNAL OF DERMATOLOGY 144(6):1292-1293 Passeron T; Lacour JP; Murr D; Ortonne JP Thalidomide-induced amenorrhoea: two cases | 4 | 4 |
603 | 10 | 51 | 1163 2001 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
604 | 92 | 115 | 1177 2001 DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
605 | 44 | 67 | 1184 2001 DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
606 | 21 | 36 | 1283 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 4 | 15 |
607 | 14 | 29 | 1420 2002 CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 27 |
608 | 12 | 49 | 1429 2002 CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 8 |
609 | 102 | 164 | 1440 2002 DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
610 | 11 | 22 | 1468 2002 INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153 Shannon EJ; Sandoval FG Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant | 4 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
611 | 16 | 24 | 1480 2002 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 4 | 5 |
612 | 4 | 5 | 1486 2002 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212 Cany L; Fitoussi O; Boiron JM; Marit G Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma | 4 | 4 |
613 | 7 | 20 | 1504 2002 JOURNAL OF PEDIATRICS 140(1):125-127 Lehman TJA; Striegel KH; Onel KB Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis | 4 | 8 |
614 | 7 | 29 | 1523 2002 LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
615 | 7 | 17 | 1530 2002 MEDICAL ONCOLOGY 19(2):79-86 Merup M; Kutti J; Birgergard G; Mauritzson N; Bjorkholm M; Markevarn B; Malm C; Westin J; Palmblad J; Samuelsson J; Swedish Natl Study Grp Chronic Mye Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | 4 | 5 |
616 | 6 | 24 | 1543 2002 PHARMACEUTICAL RESEARCH 19(1):13-19 Goosen C; Laing TJ; du Plessis J; Goosen TC; Flynn GL Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs | 4 | 4 |
617 | 8 | 20 | 1671 2003 BRITISH JOURNAL OF CANCER 88(6):822-827 Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer | 4 | 10 |
618 | 19 | 31 | 1693 2003 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 4 | 6 |
619 | 7 | 25 | 1744 2003 JOURNAL OF CLINICAL ONCOLOGY 21(14):2732-2739 Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma | 4 | 11 |
620 | 7 | 26 | 1745 2003 JOURNAL OF CLINICAL ONCOLOGY 21(17):3351-3356 Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | 4 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
621 | 0 | 5 | 11 1981 DERMATOLOGICA 162(2):86-90 SHESKIN J; GORODETZKY R; LOEWINGER E; WEINREB A INVIVO MEASUREMENTS OF IRON, COPPER AND ZINC IN THE SKIN OF PRURIGO NODULARIS PATIENTS TREATED WITH THALIDOMIDE | 3 | 11 |
622 | 0 | 13 | 14 1981 EUROPEAN JOURNAL OF PEDIATRICS 136(3):229-230 BURGIO GR THE THALIDOMIDE DISASTER BRIEFLY REVISITED | 3 | 4 |
623 | 0 | 8 | 34 1981 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 36(9-10):904-906 KOCHERBECKER U; KOCHER W; OCKENFELS H THALIDOMIDE-LIKE MALFORMATIONS CAUSED BY A TWEEN SURFACTANT IN MICE | 3 | 6 |
624 | 1 | 10 | 49 1982 NATURWISSENSCHAFTEN 69(4):191-192 KOCHERBECKER U; KOCHER W; OCKENFELS H TERATOGENIC ACTIVITY OF A HYDROLYTIC THALIDOMIDE METABOLITE IN MICE | 3 | 4 |
625 | 0 | 4 | 62 1983 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 110(6-7):551-552 NOUGUE J; NOUGUE M; BAZEX J; HAYEK JP; BIDOUZE H OCCURRENCE OF A GENITAL HEMORRHAGIC DURING A THALIDOMIDE TREATED PRURIGO NODULARIS | 3 | 3 |
626 | 0 | 0 | 80 1983 CLINICAL RESEARCH 31(5):A920-A920 DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE; MILLIKAN LE THALIDOMIDE INDUCED ALTERATION OF HUMAN PERIPHERAL-BLOOD MONOCYTE ACTIVITY | 3 | 3 |
627 | 2 | 12 | 87 1983 HAUTARZT 34(4):175-178 VOLCPLATZER B; WOLFF K TREATMENT OF SUBACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 3 | 6 |
628 | 0 | 29 | 100 1983 TERATOLOGY 27(3):327-332 PARKHIE M; WEBB M EMBRYOTOXICITY AND TERATOGENICITY OF THALIDOMIDE IN RATS | 3 | 7 |
629 | 0 | 42 | 118 1984 JOURNAL OF ANATOMY 139(OCT):397-410 MCCREDIE J; NORTH K; DEIONGH R THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 3 | 7 |
630 | 1 | 6 | 125 1984 REVUE DU RHUMATISME 51(10):585-585 TREVES R; ARNAUD M; JACOB P; LUBEAU M; TABARAUD F; BURKI F; DESPROGESGOTTERON R DRAMATIC IMPROVEMENT IN THE ARTHRITIS OF BEHCETS-DISEASE FOLLOWING THE ADMINISTRATION OF THALIDOMIDE - A CASE-REPORT | 3 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
631 | 0 | 17 | 169 1985 PSYCHOPHARMACOLOGY 85(1):47-50 KAITIN KI EFFECTS OF THALIDOMIDE AND PENTOBARBITAL ON NEURONAL-ACTIVITY IN THE PREOPTIC AREA DURING SLEEP AND WAKEFULNESS IN THE CAT | 3 | 6 |
632 | 4 | 11 | 232 1988 FUNDAMENTAL & CLINICAL PHARMACOLOGY 2(6):493-497 DESCOTES J; TEDONE R; EVREUX JC ENHANCEMENT OF ANTIBODY-RESPONSE AND DELAYED-TYPE HYPERSENSITIVITY BY THALIDOMIDE IN MICE | 3 | 3 |
633 | 2 | 40 | 282 1990 JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 49(6):564-581 DEIONGH RU A QUANTITATIVE ULTRASTRUCTURAL-STUDY OF MOTOR AND SENSORY LUMBOSACRAL NERVE ROOTS IN THE THALIDOMIDE-TREATED RABBIT FETUS | 3 | 3 |
634 | 0 | 0 | 290 1990 MEDICINA CLINICA 94(16):638-639 BERNARDO P; ARRIZABALAGA J; IRIBARREN JA; GARDE C EFFECTIVENESS OF THALIDOMIDE IN NONSPECIFIC ESOPHAGEAL ULCERS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY SYNDROME | 3 | 4 |
635 | 8 | 10 | 318 1992 ARCHIVES OF INTERNAL MEDICINE 152(5):1089-1090 BOUZA E; MUNOZ P; DIAZ MD; VICENTE T THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 3 | 6 |
636 | 0 | 31 | 322 1992 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 230(2):140-149 STROMLAND K; MILLER MT REFRACTIVE EVALUATION IN THALIDOMIDE EMBRYOPATHY | 3 | 5 |
637 | 5 | 6 | 332 1992 LANCET 339(8805):1362-1362 CARMICHAEL AJ; KNIGHT A THALIDOMIDE - A RESTRICTED ROLE | 3 | 5 |
638 | 2 | 3 | 375 1993 PRESSE MEDICALE 22(26):1233-1233 BODOKH I; LACOUR JP; RAINERO C; CASTANET J; MICHIELS JF; ORTONNE JP EFFECTIVENESS OF THALIDOMIDE AGAINST ESOPHAGEAL ULCERATION IN HIV-INFECTION | 3 | 3 |
639 | 5 | 32 | 385 1994 BIOGENIC AMINES 10(6):543-554 AUDIT CO THALIDOMIDE-INDUCED POLYAMINE ACYLATION - A NEW INSIGHT INTO THE ACYLATION MECHANISM | 3 | 3 |
640 | 0 | 0 | 390 1994 BRITISH MEDICAL JOURNAL 308(6936):1061-1061 ROCHA J THALIDOMIDE GIVEN TO WOMEN IN BRAZIL | 3 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
641 | 2 | 19 | 403 1994 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 36(4):351-356 STROMLAND K; NORDIN V; MILLER M; AKERSTROM B; GILLBERG C AUTISM IN THALIDOMIDE EMBRYOPATHY - A POPULATION STUDY | 3 | 71 |
642 | 9 | 20 | 411 1994 JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2 (9):2063-2067 REEPMEYER JC; RHODES MO; COX DC; SILVERTON JV CHARACTERIZATION AND CRYSTAL-STRUCTURE OF 2 POLYMORPHIC FORMS OF RACEMIC THALIDOMIDE | 3 | 4 |
643 | 7 | 45 | 417 1994 LIFE SCIENCES 56(6):407-420 NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .4. DOWN-REGULATION OF THE CD26 RECEPTOR, PROBABLY INVOLVED IN THE BINDING OF HIV COMPONENTS TO T-CELLS IN PRIMATES | 3 | 4 |
644 | 0 | 0 | 420 1994 PANMINERVA MEDICA 36(1):1-4 VOSGERAU JCB AUTOIMMUNITY IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND THE USE OF THALIDOMIDE | 3 | 3 |
645 | 0 | 8 | 431 1995 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 122(9):609-611 Safa G; Joly P; Boullie MC; Thomine E; Lauret P Treatment of 2 cases of Melkersson-Rosenthal syndrome with thalidomide | 3 | 8 |
646 | 4 | 22 | 434 1995 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 39(12):2807-2809 PETERSON PK; GEKKER G; BORNEMANN M; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS LIPOARABINOMANNAN-INDUCED UP-REGULATION OF HUMAN-IMMUNODEFICIENCY-VIRUS EXPRESSION | 3 | 10 |
647 | 14 | 38 | 474 1995 LIFE SCIENCES 58(4):295-316 Neubert R; Hinz N; Thiel R; Neubert D Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide | 3 | 7 |
648 | 0 | 0 | 481 1995 NATURE MEDICINE 1(12):1230-1230 GERSHON D FINDING NEW USES FOR THALIDOMIDE | 3 | 5 |
649 | 8 | 16 | 495 1996 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 53(4):429-431 Minor JR; Piscitelli SC Thalidomide in diseases associated with human immunodeficiency virus infection | 3 | 4 |
650 | 8 | 22 | 504 1996 ARCHIVES OF TOXICOLOGY 70(11):749-756 Schmahl HJ; Dencker L; Plum C; Chahoud I; Nau H Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse | 3 | 7 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
651 | 22 | 33 | 549 1996 LUPUS 5(4):257-258 Stevens RJ The place of thalidomide in the treatment of inflammatory disease | 3 | 5 |
652 | 19 | 42 | 593 1997 CLINICAL NEUROPHARMACOLOGY 20(2):152-164 Zhu J; Bai XF; Mix E; vanderMeide PH; Zwingenberger K; Link H Thalidomide suppresses T-and B-cell responses to myelin antigen in experimental allergic neuritis | 3 | 4 |
653 | 2 | 5 | 637 1997 NATURE 389(6647):118-118 Ashby J Thalidomide is not a mutagen | 3 | 4 |
654 | 4 | 11 | 653 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):R1-R2 Neubert D Never-ending tales of the mode of the teratogenic action of thalidomide | 3 | 5 |
655 | 7 | 10 | 690 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(3):141-141 Georgala S; Katoulis AC; Hasapi V; Koumantaki-Mathioudaki E Thalidomide treatment for hypertrophic lupus erythematosus | 3 | 3 |
656 | 10 | 15 | 713 1998 JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 21(14):2151-2163 Haque A; Stewart JT Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction | 3 | 5 |
657 | 3 | 5 | 740 1998 REVUE DE MEDECINE INTERNE 19(3):208-209 Grasland A; Pouchot J; Chaumaiziere D; Aitken G; Vinceneux P Effectiveness of thalidomide in cutaneous sarcoidosis | 3 | 4 |
658 | 13 | 16 | 789 1999 CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
659 | 12 | 70 | 800 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
660 | 0 | 0 | 805 1999 GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
661 | 3 | 10 | 842 1999 LUPUS 8(3):248-249 Rua-Figueroa I; Erausquin C; Naranjo A; Carretero-Hernandez G; Rodriguez-Lozano C; De la Rosa P Pustuloderma during cutaneous lupus treatment with thalidomide | 3 | 5 |
662 | 23 | 79 | 845 1999 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
663 | 4 | 11 | 846 1999 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
664 | 16 | 39 | 855 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 14 |
665 | 3 | 8 | 860 1999 PHARMACOLOGY & TOXICOLOGY 85(2):103-104 Huang PHT; McBride WG; Tuman WG Interaction of thalidomide with DNA of rabbit embryos: A possible explanation for its immunosuppressant and teratogenic effects | 3 | 3 |
666 | 12 | 17 | 863 1999 REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 9 |
667 | 3 | 9 | 871 2000 ACTA DERMATO-VENEREOLOGICA 80(1):24-25 Daly BM; Shuster S Antipruritic action of thalidomide | 3 | 9 |
668 | 9 | 60 | 878 2000 AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 3 | 24 |
669 | 7 | 23 | 969 2000 DIABETES CARE 23(8):1172-1176 Iqbal N; Zayed M; Boden G Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes | 3 | 3 |
670 | 10 | 34 | 975 2000 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
671 | 1 | 1 | 1001 2000 JOURNAL OF CHILD NEUROLOGY 15(12):838-838 Schoeman JF Thalidomide therapy in childhood tuberculous meningitis | 3 | 4 |
672 | 13 | 41 | 1002 2000 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 32 |
673 | 9 | 15 | 1009 2000 JOURNAL OF INFECTIOUS DISEASES 181(5):1813-1816 Juffermans NP; Verbon A; Olszyna DP; van Deventer SJH; Speelman P; van der Poll T Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4(+) T cells in humans | 3 | 5 |
674 | 5 | 16 | 1020 2000 LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
675 | 1 | 1 | 1031 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-975 Kishi Y; Oki Y; Machida U Thalidomide in multiple myeloma | 3 | 5 |
676 | 3 | 18 | 1059 2000 TETRAHEDRON LETTERS 41(14):2275-2278 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites. Part 1: Derivatives of (+)-2-(N-phthalimido)-gamma-hydroxyglutamic acid | 3 | 7 |
677 | 32 | 44 | 1068 2001 AMERICAN JOURNAL OF THE MEDICAL SCIENCES 321(5):321-326 Moraes M; Russo G Thalidomide and its dermatologic uses | 3 | 9 |
678 | 3 | 5 | 1078 2001 ARCHIVES OF INTERNAL MEDICINE 161(20):2502-2503 Rajkumar SV; Fonseca R; Witzig TE Complete resolution of reflex sympathetic dystrophy with thalidomide treatment | 3 | 4 |
679 | 14 | 32 | 1090 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
680 | 10 | 38 | 1145 2001 BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
681 | 8 | 38 | 1159 2001 BRITISH JOURNAL OF PHARMACOLOGY 133(8):1414-1423 Lienenluke B; Stojanovic T; Fiebig T; Fayyazi A; Germann T; Hecker M Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat-role of endothelial cell-leukocyte interaction | 3 | 4 |
682 | 6 | 6 | 1194 2001 GASTROENTEROLOGY 120(6):1567-1568 Fox MR; Harris A Intractable insomnia after cessation of treatment with thalidomide | 3 | 3 |
683 | 5 | 20 | 1206 2001 HAUTARZT 52:962-965 Hoch O; Muller S; Buttner G; Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 3 | 5 |
684 | 10 | 27 | 1221 2001 JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364 Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues | 3 | 4 |
685 | 20 | 32 | 1224 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(6):662-667 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Thalidomide dose proportionality assessment following single doses to healthy subjects | 3 | 4 |
686 | 10 | 15 | 1229 2001 JOURNAL OF INFECTIOUS DISEASES 184(9):1192-1196 Hanekom WA; Hughes J; Haslett PAJ; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children | 3 | 3 |
687 | 6 | 6 | 1236 2001 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966 George SJ; Hsu S Lichen planopilaris treated with thalidomide | 3 | 6 |
688 | 0 | 5 | 1237 2001 LANCET ONCOLOGY 2(10):634-635 Hwu WJ; Raizer J; Panageas KS; Lis E Treatment of metastatic melanoma in the brain with temozolomide and thalidomide | 3 | 7 |
689 | 11 | 27 | 1290 2002 AMERICAN JOURNAL OF MEDICINE 113(7):603-606 Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W Thalidomide-associated deep vein thrombosis and pulmonary embolism | 3 | 6 |
690 | 4 | 6 | 1296 2002 ANNALS OF ONCOLOGY 13(10):1636-1640 Grover JK; Uppal G; Raina V The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma | 3 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
691 | 9 | 36 | 1299 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(6):1887-1895 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis | 3 | 5 |
692 | 8 | 14 | 1302 2002 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 47(3):249-254 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY One-year open-label trial of thalidomide in ankylosing spondylitis | 3 | 11 |
693 | 15 | 82 | 1309 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
694 | 30 | 59 | 1390 2002 BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
695 | 0 | 0 | 1395 2002 BRITISH JOURNAL OF CANCER 86:S26-S26 Marriott JB; Clarke IA; Dredge K; Pandha H; Kristaleit H; Polychronis A; Muller GW; Stirling D; Dalgleish AG Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation | 3 | 3 |
696 | 12 | 38 | 1456 2002 GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 14 |
697 | 18 | 23 | 1459 2002 HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
698 | 4 | 7 | 1460 2002 HAEMATOLOGICA 87(3):327-328 Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M Advantages of using thalidomide for the management of patients with refractory myeloma | 3 | 4 |
699 | 14 | 28 | 1476 2002 JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
700 | 10 | 15 | 1481 2002 JOURNAL OF CLINICAL GASTROENTEROLOGY 35(2):149-150 Kane S; Stone LJ; Ehrenpreis E Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab - A case series | 3 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
701 | 5 | 23 | 1522 2002 LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
702 | 17 | 38 | 1526 2002 LUPUS 11(2):67-70 Piette JC; Sbai A; Frances C Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus | 3 | 5 |
703 | 3 | 21 | 1544 2002 PHARMACEUTICAL RESEARCH 19(4):434-439 Goosen C; Laing TJ; du Plessis J; Goosen TC; Lu GW; Flynn GL Percutaneous delivery of thalidomide and its N-alkyl analogs | 3 | 4 |
704 | 10 | 18 | 1545 2002 PHARMACEUTICAL RESEARCH 19(8):1232-1235 Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs | 3 | 3 |
705 | 8 | 11 | 1550 2002 REVUE DE MEDECINE INTERNE 23(8):724-727 Gachon J; Grob JJ; Richard MA Thalidomide treatment leading thrombotic events: two cases | 3 | 4 |
706 | 17 | 35 | 1553 2002 TERATOLOGY 66(3):115-121 Stromland K; Philipson E; Gronlund MA Offspring of male and female parents with thalidomide embryopathy: Birth defects and functional anomalies | 3 | 5 |
707 | 22 | 30 | 1582 2003 ANTI-CANCER DRUGS 14(5):331-335 Dredge K; Dalgleish AG; Marriott JB Thalidomide analogs as emerging anti-cancer drugs | 3 | 8 |
708 | 9 | 31 | 1695 2003 CHEMICAL & PHARMACEUTICAL BULLETIN 51(9):1098-1102 Suizu M; Muroya Y; Kakuta H; Kagechika H; Tanatani A; Nagasawa K; Hashimoto Y Cyclooxygenase inhibitors derived from thalidomide | 3 | 3 |
709 | 4 | 20 | 1704 2003 CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 3 | 6 |
710 | 40 | 59 | 1709 2003 CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
711 | 73 | 144 | 1720 2003 EXPERT OPINION ON INVESTIGATIONAL DRUGS 12(7):1211-1225 Fanelli M; Sarmiento R; Gattuso D; Carillio G; Capaccetti B; Vacca A; Roccaro AM; Gasparini G Thalidomide: a new anticancer drug? | 3 | 7 |
712 | 9 | 39 | 1760 2003 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
713 | 13 | 23 | 1761 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
714 | 10 | 14 | 1763 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
715 | 3 | 7 | 1802 2003 NEUROLOGY 60(5):877-878 Giannini F; Volpi N; Rossi S; Passero S; Fimiani M; Cerase A Thalidomide-induced neuropathy: a ganglionopathy? | 3 | 3 |
716 | 15 | 21 | 1811 2003 PHARMACOTHERAPY 23(3):315-318 Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer | 3 | 4 |
717 | 6 | 25 | 1823 2003 SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 3 | 5 |
718 | 7 | 29 | 1824 2003 SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 6 |
719 | 0 | 40 | 33 1981 TERATOLOGY 23(3):351-364 NEWMAN LM; HENDRICKX AG FETAL EAR MALFORMATIONS INDUCED BY MATERNAL INGESTION OF THALIDOMIDE IN THE BONNET MONKEY (MACACA, RADIATA) | 2 | 13 |
720 | 1 | 10 | 45 1982 DEVELOPMENT GROWTH & DIFFERENTIATION 24(2):217-222 MCBRIDE WG; STOKES PA; VARDY PH MATERNAL THALIDOMIDE TREATMENT AND CELL-DIVISION IN CULTURED RABBIT EMBRYOS - AUTOMATED IMAGE-ANALYSIS OF AUTORADIOGRAPHS | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
721 | 1 | 17 | 66 1983 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 16(2):105-109 SCHMIDT M; SALZANO FM CLINICAL-STUDIES ON TEENAGE BRAZILIAN VICTIMS OF THALIDOMIDE | 2 | 3 |
722 | 2 | 5 | 74 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 EFTHIMIOU J; SPIRO SG EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 2 | 2 |
723 | 0 | 14 | 86 1983 HAUTARZT 34(4):168-170 SHESKIN J; MUCKTER H; FRANKUS E SUPIDIMIDE, A NON-TERATOGENIC ANALOG OF THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS | 2 | 2 |
724 | 1 | 2 | 162 1985 LANCET 1(8427):511-511 JENKINS S; POWELL RJ; ALLEN BR; LITTLEWOOD S; MAURICE PD; SMITH NJ THALIDOMIDE, OROGENITAL ULCERS, AND RISK OF TERATOGENICITY | 2 | 3 |
725 | 2 | 8 | 177 1986 ARTHRITIS AND RHEUMATISM 29(10):1296-1296 SHEEHAN NJ THALIDOMIDE NEUROTOXICITY AND RHEUMATOID-ARTHRITIS | 2 | 2 |
726 | 1 | 10 | 219 1988 ARCHIV DER PHARMAZIE 321(6):371-373 KOCH HP; STEINACKER C IMPROVEMENT OF SOLUBILITY AND STABILITY OF THALIDOMIDE BY INCLUSION COMPLEXATION WITH CYCLODEXTRINS | 2 | 4 |
727 | 4 | 5 | 226 1988 ARTHRITIS AND RHEUMATISM 31(1):145-146 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O THALIDOMIDE-INDUCED NEUROPATHY IN RHEUMATOID-ARTHRITIS PATIENTS | 2 | 4 |
728 | 0 | 17 | 245 1988 TERATOLOGY 38(3):217-219 WARKANY J WHY I DOUBTED THAT THALIDOMIDE WAS THE CAUSE OF THE EPIDEMIC OF LIMB DEFECTS OF 1959 TO 1961 | 2 | 3 |
729 | 0 | 17 | 251 1989 ARCHIV DER PHARMAZIE 322(8):499-505 KNABE J; OMLOR G SYNTHESES OF THE RACEMATES AND THE ENANTIOMERS OF ANALOGS OF THALIDOMIDE ALKYLATED IN 3-POSITION AND DETERMINATION OF THEIR ABSOLUTE-CONFIGURATION | 2 | 4 |
730 | 1 | 6 | 258 1989 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 13(1):104-104 PATEY O; CHARASZ N; ROUCAYROL AM; MALKIN JE; LAFAIX C THALIDOMIDE AND INTESTINAL INVOLVEMENT IN BEHCETS SYNDROME | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
731 | 7 | 33 | 266 1990 ACTA ENDOCRINOLOGICA 123(1):79-83 LUEPRASITSAKUL W; ABEND S; ALEX S; REINHARDT W; APPEL MC; BRAVERMAN LE EFFECT OF THALIDOMIDE ON THE INCIDENCE OF IODINE-INDUCED AND SPONTANEOUS LYMPHOCYTIC THYROIDITIS AND SPONTANEOUS DIABETES-MELLITUS IN THE BB/WOR RAT | 2 | 2 |
732 | 0 | 2 | 279 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1473-1473 RANDALL T RESEARCH FOCUSES ON IMMUNOSUPPRESSIVE EFFECT, UNKNOWN TERATOGENIC MECHANISM OF THALIDOMIDE | 2 | 2 |
733 | 1 | 4 | 292 1990 PRESSE MEDICALE 19(15):722-722 SAMSON J; KUFFER R; RADEFF B THALIDOMIDE TREATMENT OF CHOICE OF APHTHAE IN HIV-INFECTION | 2 | 2 |
734 | 4 | 19 | 296 1990 TERATOLOGY 41(2):243-244 KOCH HP PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 2 | 4 |
735 | 2 | 11 | 305 1991 BRITISH MEDICAL JOURNAL 303(6814):1404-1405 HOOPER M USE OF THALIDOMIDE IN LEPROSY | 2 | 2 |
736 | 7 | 23 | 306 1991 CANCER LETTERS 60(2):129-133 GERSHBEIN LL THE THALIDOMIDE ANALOG, EM-12, ENHANCES 1,2-DIMETHYLHYDRAZINE-INDUCTION OF RAT COLON ADENOCARCINOMAS | 2 | 6 |
737 | 1 | 2 | 336 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 VOGELSANG GB THALIDOMIDE NEUROPATHY - REPLY | 2 | 2 |
738 | 0 | 0 | 339 1992 TERATOLOGY 46(5):417-418 LENZ W A PERSONAL PERSPECTIVE ON THE THALIDOMIDE TRAGEDY | 2 | 5 |
739 | 0 | 0 | 343 1992 TROPICAL DOCTOR 22(3):139-140 WATERS MFR THALIDOMIDE PERIPHERAL NEUROPATHY - REPLY | 2 | 4 |
740 | 1 | 3 | 374 1993 PRESSE MEDICALE 22(1):37-37 PEDAILLES S; TROUSSARD X; LAUNAY V; BAZIN A; SENTIAS C; SURBLED M SCLERODERMATOUS SKIN REACTION IN GRAFT-VERSUS-HOST DISEASE TREATED WITH THALIDOMIDE | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
741 | 0 | 0 | 389 1994 BRITISH MEDICAL JOURNAL 308(6931):739-739 CHRISTIE B THALIDOMIDE VICTIMS WIN REVIEW OF COMPENSATION | 2 | 2 |
742 | 1 | 3 | 394 1994 BRITISH MEDICAL JOURNAL 309(6948):193-194 ASSCHER W SAFETY OF THALIDOMIDE | 2 | 2 |
743 | 4 | 28 | 441 1995 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 28(10):1069-1076 AARESTRUP FM; GONCALVESDACOSTA SC; SARNO EN THE EFFECT OF THALIDOMIDE ON BCG-INDUCED GRANULOMAS IN MICE | 2 | 9 |
744 | 5 | 5 | 459 1995 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 19(1):128-129 SIRE S; FRAISSE P; REY D; JACQUEMIN C; KEMPF G; PARTISANI M; LANG JM EFFECTIVENESS OF THALIDOMIDE IN THE TREATMENT OF ESOPHAGEAL ULCERS IN AIDS | 2 | 2 |
745 | 0 | 0 | 467 1995 JOURNAL OF INVESTIGATIVE DERMATOLOGY 105(3):479-479 CHARUE D; CHAUVIN E; DUGUET C; REVUZ J; BAGOT M THALIDOMIDE DECREASES THE PRODUCTION OF GM-CSF AND TNF-ALPHA IN MIXED EPIDERMAL-CELL LYMPHOCYTE-REACTION | 2 | 2 |
746 | 11 | 24 | 475 1995 LIFE SCIENCES 58(4):337-348 Nogueira AC; Neubert R; Felies A; JacobMuller U; Frankus E; Neubert D Thalidomide derivatives and the immune system .6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets | 2 | 3 |
747 | 11 | 39 | 522 1996 DEVELOPMENT GROWTH & DIFFERENTIATION 38(1):47-57 Audit CO; Eger K; Aimar C Possible involvement of an acylation mechanism in thalidomide-induced teratogenesis of the newt (Pleurodeles waltl) | 2 | 2 |
748 | 1 | 13 | 535 1996 INTERNATIONAL JOURNAL OF STD & AIDS 7(7):518-520 Lewis DA; Amerasinghe CN; Murphy SM Successful treatment of Behcet's syndrome in an African female patient with thalidomide | 2 | 3 |
749 | 0 | 0 | 542 1996 JOURNAL OF INVESTIGATIVE DERMATOLOGY 106(4):845-845 Smith C; Friednash M; Nguyen C; Knauf T; Walsh P Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model | 2 | 3 |
750 | 0 | 0 | 558 1996 REPRODUCTIVE TOXICOLOGY 10(1):1-2 Robert E Thalidomide and isotretinoin - Why treat them differently? | 2 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
751 | 0 | 0 | 572 1997 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(20):2270-& Miller JL Thalidomide recommended for approval under tight restrictions | 2 | 2 |
752 | 0 | 0 | 616 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):20-20 Welles L; Little R; Wyvill K; Pluda J; Figg W; Lietzau J; Merced T; Humphrey R; Yarchoan R Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS) | 2 | 3 |
753 | 3 | 4 | 618 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 15(5):392-392 Sharp M; Getty J; Klausner JD Thalidomide use is associated with weight gain in HIV-1-positive clients | 2 | 2 |
754 | 10 | 20 | 647 1997 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 84(4):362-364 Elad S; Galili D; Garfunkel AA; Or R Thalidomide-induced perioral neuropathy | 2 | 3 |
755 | 7 | 10 | 658 1998 AIDS PATIENT CARE AND STDS 12(12):903-906 Fu CS; Conteas CN; LaRiviere MJ Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus | 2 | 3 |
756 | 0 | 0 | 665 1998 ARTHRITIS AND RHEUMATISM 41(9):S60-S60 Scoville CD Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis. | 2 | 2 |
757 | 2 | 19 | 729 1998 METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 20(9):739-742 Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model | 2 | 5 |
758 | 0 | 0 | 758 1999 ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
759 | 4 | 5 | 791 1999 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
760 | 12 | 34 | 801 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
761 | 0 | 0 | 803 1999 GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
762 | 0 | 0 | 804 1999 GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
763 | 0 | 0 | 806 1999 GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
764 | 1 | 3 | 850 1999 NATURE MEDICINE 5(8):853-853 Guenzler V Mechanisms of thalidomide teratogenicity | 2 | 3 |
765 | 7 | 12 | 875 2000 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 57(17):1607-1610 Eriksson T; Wallin R; Hoglund P; Roth B; Qi ZQ; Ostraat O; Bjorkman S Low bioavailability of rectally administered thalidomide | 2 | 2 |
766 | 6 | 20 | 890 2000 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
767 | 0 | 0 | 892 2000 ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
768 | 7 | 20 | 973 2000 EUROPEAN CYTOKINE NETWORK 11(4):574-579 van Crevel R; Vonk AG; Netea MG; Kullberg BJ; van der Meer JWM Modulation of LPS-, PHA-and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide | 2 | 3 |
769 | 92 | 148 | 1028 2000 NATIONAL MEDICAL JOURNAL OF INDIA 13(3):132-141 Grover JK; Vats V; Gopalakrishna R; Ramam M Thalidomide: A re-look | 2 | 3 |
770 | 0 | 0 | 1037 2000 ONCOLOGY-NEW YORK 14(12):9-10 Rajkumar SV Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
771 | 7 | 18 | 1042 2000 ONCOLOGY-NEW YORK 14(12):33-36 Amato R Thalidomide for recurrent renal-cell cancer in a 40-year-old man | 2 | 2 |
772 | 5 | 14 | 1077 2001 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 45(5):1547-1549 Juffermans NP; Verbon A; Schultz MJ; Hack CE; van Deventer SJH; Speelman P; van der Poll T Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens | 2 | 2 |
773 | 6 | 6 | 1083 2001 ARTHRITIS AND RHEUMATISM 44(10):2456-2457 Lee L; Lawford R; McNeil HP The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: comment on the letter by Breban et al | 2 | 5 |
774 | 1 | 4 | 1084 2001 ARTHRITIS AND RHEUMATISM 44(10):2457-2458 Breban M; Dougados M The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: Reply | 2 | 5 |
775 | 2 | 23 | 1085 2001 BIOCHEMICAL PHARMACOLOGY 62(8):1081-1086 Onat D; Stahl W; Sies H Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344) | 2 | 3 |
776 | 13 | 41 | 1091 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(5):1279-1291 Hess S; Akermann MA; Wnendt S; Zwingerberger K; Eger K Synthesis and immunological activity of water-soluble thalidomide prodrugs | 2 | 4 |
777 | 1 | 3 | 1153 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):245-245 Myers B; Grimley C; Dolan G Thalidomide and low-dose dexamethasone in myeloma treatment | 2 | 3 |
778 | 3 | 4 | 1154 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(1):234-234 Myers B; Grimley C; Crouch D; Dolan G Lack of response to thalidomide in plasmacytomas | 2 | 4 |
779 | 7 | 37 | 1161 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(4):319-326 Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac | 2 | 10 |
780 | 7 | 31 | 1162 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
781 | 7 | 25 | 1172 2001 CLINICAL CANCER RESEARCH 7(11):3311-3313 Onn A; Tseng JE; Herbst RS Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy | 2 | 11 |
782 | 26 | 123 | 1176 2001 CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
783 | 30 | 49 | 1178 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
784 | 14 | 63 | 1181 2001 DRUG DEVELOPMENT RESEARCH 54(4):209-218 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat | 2 | 3 |
785 | 24 | 28 | 1234 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(3):322-324 Strauss RS; Das FM Thalidomide-induced sensory neuropathy | 2 | 3 |
786 | 6 | 15 | 1258 2001 OPHTHALMOLOGICA 215(1):70-73 Parentin F; Da Pozzo S; Lepore L; Perissutti P Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child | 2 | 2 |
787 | 7 | 40 | 1259 2001 OPHTHALMOLOGICA 215(4):284-289 Kaven C; Spraul CW; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro | 2 | 7 |
788 | 13 | 18 | 1265 2001 REVUE DE MEDECINE INTERNE 22(1):5-7 Grosbois B; Duguet C Thalidomide: the revival | 2 | 4 |
789 | 12 | 25 | 1273 2001 SEMINARS IN ONCOLOGY 28(6):593-596 Desikan RK; Jagannath S Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions | 2 | 2 |
790 | 3 | 4 | 1276 2001 SWISS MEDICAL WEEKLY 131(9-10):133-133 Trojan A; Anagnostara A; Fost L Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
791 | 3 | 33 | 1314 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(9):3067-3073 Lima LM; Castro P; Machado AL; Fraga CAM; Lugnier C; de Moraes VLG; Barreiro EJ Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues | 2 | 6 |
792 | 4 | 4 | 1319 2002 BLOOD 99(11):4248-4248 Lee FC Second response to lower-dose thalidomide in a patient with multiple myeloma | 2 | 2 |
793 | 10 | 23 | 1414 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 2 | 2 |
794 | 75 | 130 | 1423 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
795 | 19 | 30 | 1474 2002 INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572 Fu LM; Fu-Liu CS Thalidomide and tuberculosis | 2 | 3 |
796 | 16 | 34 | 1478 2002 JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
797 | 23 | 30 | 1500 2002 JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945 Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide | 2 | 6 |
798 | 10 | 40 | 1507 2002 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 300(3):768-776 Hansen JM; Harris KK; Philbert MA; Harris C Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb | 2 | 5 |
799 | 4 | 26 | 1521 2002 LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
800 | 3 | 5 | 1525 2002 LEUKEMIA RESEARCH 26(10):965-966 Tsirigotis P; Venetis E; Rontogianni D; Dervenoulas J; Kontopidou F; Apostolidis P Thalidomide in the treatment of myelodysplastic syndrome with fibrosis | 2 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
801 | 9 | 9 | 1578 2003 ANNALS OF ONCOLOGY 14(3):501-502 Trojan A; Chasse E; Gay B; Pichert G; Taverna C Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma | 2 | 2 |
802 | 11 | 30 | 1588 2003 ARCHIVES OF DERMATOLOGY 139(1):50-54 Housman TS; Jorizzo JL; McCarty MA; Grummer SE; Fleischer AB; Sutej PG Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | 2 | 4 |
803 | 4 | 7 | 1680 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 2 | 2 |
804 | 5 | 6 | 1681 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):160-161 Harris E; Behrens J; Samson D; Rahemtulla A; Russell NH; Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia | 2 | 3 |
805 | 4 | 10 | 1683 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(2):305-308 Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2 | 4 |
806 | 5 | 34 | 1689 2003 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 2 | 7 |
807 | 156 | 221 | 1706 2003 CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 6 |
808 | 16 | 37 | 1713 2003 DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
809 | 5 | 41 | 1734 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
810 | 4 | 37 | 1742 2003 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 2 | 5 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
811 | 5 | 37 | 1743 2003 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 2 | 7 |
812 | 13 | 36 | 1746 2003 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 2 | 4 |
813 | 15 | 45 | 1755 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(24):5222-5229 Zhu XX; Giordano T; Yu QS; Holloway HW; Perry TA; Lahiri DK; Brossi A; Greig NH Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity | 2 | 2 |
814 | 6 | 10 | 1768 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 2 | 2 |
815 | 8 | 21 | 1769 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):445-449 Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment | 2 | 2 |
816 | 12 | 27 | 1794 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 2 | 3 |
817 | 13 | 44 | 1805 2003 ONCOLOGY 65(3):242-249 Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL Low-dose thalidomide treatment for advanced hepatocellular carcinoma | 2 | 5 |
818 | 13 | 28 | 1879 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 2 | 2 |
819 | 39 | 57 | 1965 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 2 | 2 |
820 | 0 | 3 | 1 1980 ACTA GENETICAE MEDICAE ET GEMELLOLOGIAE 29(4):295-297 SCHMIDT M; SALZANO FM DISSIMILAR EFFECTS OF THALIDOMIDE IN DIZYGOTIC TWINS | 1 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
821 | 0 | 0 | 7 1981 ARCHIVES OF GYNECOLOGY 232(1-4):611-612 MUHLENSTEDT D; SCHWARZ M GYNECOLOGICAL-ENDOCRINOLOGICAL STUDIES ON THALIDOMIDE-DAMAGED GIRLS | 1 | 1 |
822 | 0 | 0 | 21 1981 LANCET 2(8242):368-368 MCBRIDE WG ANOTHER, LATE THALIDOMIDE ABNORMALITY | 1 | 1 |
823 | 0 | 16 | 47 1982 EUROPEAN JOURNAL OF PEDIATRICS 138(1):77-80 VANREGEMORTER N; HAUMONT D; KIRKPATRICK C; VISEUR P; JEANTY P; DODION J; MILAIRE J; ROOZE M; RODESCH F HOLT ORAM SYNDROME MISTAKEN FOR THALIDOMIDE EMBRYOPATHY - EMBRYOLOGICAL CONSIDERATIONS | 1 | 6 |
824 | 0 | 0 | 75 1983 BRITISH MEDICAL JOURNAL 287(6404):1550-1550 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION - REPLY | 1 | 1 |
825 | 1 | 18 | 76 1983 BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE 96(7):910-913 VAISMAN BL; POPOV VP; IGNATEVA TV REDUCTION IN THE TISSUE ASCORBIC-ACID LEVEL IN GUINEA-PIGS BY THALIDOMIDE | 1 | 2 |
826 | 0 | 0 | 81 1983 CLINICAL RESEARCH 31(5):A921-A921 MILLIKAN LE; DOLL NJ; BARNHILL RL; HASTINGS RC; SALVAGGIO JE THE INVITRO EFFECTS OF THALIDOMIDE ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTION | 1 | 1 |
827 | 3 | 34 | 82 1983 DEVELOPMENT GROWTH & DIFFERENTIATION 25(4):361-373 MCBRIDE WG; VARDY PH PATHOGENESIS OF THALIDOMIDE TERATOGENESIS IN THE MARMOSET (CALLITHRIX-JACCHUS) - EVIDENCE SUGGESTING A POSSIBLE TROPHIC INFLUENCE OF CHOLINERGIC NERVES IN LIMB MORPHOGENESIS | 1 | 6 |
828 | 1 | 3 | 110 1984 BRITISH JOURNAL OF DERMATOLOGY 111(1):125-126 AYRES S THALIDOMIDE OR VITAMIN-E THERAPY FOR DISCOID LUPUS-ERYTHEMATOSUS | 1 | 2 |
829 | 1 | 3 | 159 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT - REPLY | 1 | 1 |
830 | 1 | 2 | 160 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 BRODTHAGEN H SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
831 | 0 | 10 | 161 1985 LANCET 1(8423):288-289 LEHNER T; SULLIVAN FM THALIDOMIDE, OROGENITAL ULCERS, AND THE RISK OF TERATOGENESIS | 1 | 3 |
832 | 2 | 8 | 164 1985 LANCET 2(8450):331-331 CRAWFORD CL THALIDOMIDE AND LEPROSY | 1 | 1 |
833 | 0 | 0 | 190 1986 LEPROSY REVIEW 57(1):76-77 LORETTI A; BARCHI E SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 1 |
834 | 1 | 1 | 191 1986 LEPROSY REVIEW 57(3):273-273 NEELAMKAVIL P SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 3 |
835 | 2 | 15 | 194 1986 REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO 28(1):12-14 ARRUDA WO; HACBARTH E; DOI E; SANTAMARIA JR; BARBOSA J; KAJDACSYBALLA AA EFFECT OF THALIDOMIDE ON SERUM LEVELS OF IMMUNOGLOBULINS IGM AND IGA, RHEUMATOID-FACTOR AND ISOHEMAGLUTININS ANTI-A AND ANTI-B IN PATIENTS WITH LEPROMATOUS LEPROSY - A DOUBLE-BLIND-STUDY | 1 | 2 |
836 | 0 | 5 | 218 1988 ANAESTHESIA 43(7):613-614 MCCRORY JW ANESTHESIA AND THALIDOMIDE-RELATED ABNORMALITIES | 1 | 1 |
837 | 2 | 5 | 231 1988 DERMATOLOGICA 176(2):107-107 VIRABEN R; DUPRE A ERYTHEMA-NODOSUM FOLLOWING THALIDOMIDE THERAPY FOR BEHCET DISEASE | 1 | 5 |
838 | 0 | 0 | 243 1988 TERATOLOGY 38(3):201-202 FRASER FC THALIDOMIDE RETROSPECTIVE - WHAT DID WE LEARN | 1 | 4 |
839 | 3 | 6 | 254 1989 BONE MARROW TRANSPLANTATION 4(5):598-598 HEATON DC FAILURE OF THALIDOMIDE TO CONTROL BRONCHIOLITIS OBLITERANS POST BONE-MARROW TRANSPLANT | 1 | 3 |
840 | 0 | 0 | 264 1989 MEDICINA CLINICA 92(15):571-571 CODINA C THALIDOMIDE 1989 | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
841 | 1 | 2 | 294 1990 TERATOLOGY 41(2):239-239 MCCREDIE J PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY - COMMENT | 1 | 1 |
842 | 3 | 10 | 297 1990 TERATOLOGY 41(2):245-246 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 1 | 3 |
843 | 0 | 0 | 313 1991 MEDICINA CLINICA 97(2):79-79 TERCEDOR J; ORTEGO N; RODENAS JM; HERNANDEZ J TREATMENT OF RECURRENT APHTHAE WITH THALIDOMIDE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME | 1 | 1 |
844 | 0 | 0 | 342 1992 TROPICAL DOCTOR 22(3):139-139 AWOFESO N THALIDOMIDE PERIPHERAL NEUROPATHY | 1 | 4 |
845 | 3 | 4 | 356 1993 BRITISH MEDICAL JOURNAL 307(6909):939-940 BURROWS NP DIAGNOSIS AND MANAGEMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS - THALIDOMIDE MODIFIES DISEASE | 1 | 1 |
846 | 0 | 0 | 360 1993 CLINICAL RESEARCH 41(2):A496-A496 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 1 | 1 |
847 | 0 | 0 | 387 1994 BLOOD 84(10):A431-A431 SCHLEGEL PG; FERNANDEZ LP; BAKER J; CHEN Y; CHAO NJ THALIDOMIDE DOES NOT MODULATE THE IL-2 RESPONSE OF ACTIVATED JURKAT CELLS AS MEASURED BY BETA-GAL-ACTIVITY AND BY IL-2 PRODUCTION | 1 | 1 |
848 | 2 | 30 | 418 1994 MIKROCHIMICA ACTA 117(1-2):75-85 AUCELIO RQ; CAMPIGLIA AD PHARMACEUTICAL FORMULATION ANALYSIS OF THALIDOMIDE BY SOLID-SURFACE ROOM-TEMPERATURE PHOSPHORIMETRY | 1 | 10 |
849 | 0 | 0 | 436 1995 ARTHRITIS AND RHEUMATISM 38(6):R10-R10 OLIVER SJ; CHENG TP; BANQUERIGO ML; BRAHN E THALIDOMIDE ANALOGS SUPPRESS RAT COLLAGEN ARTHRITIS | 1 | 2 |
850 | 1 | 1 | 457 1995 EXPERIMENTAL HEMATOLOGY 23(12):1324-1324 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION (VOL 23, PG 978, 1995) | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
851 | 6 | 29 | 460 1995 GENERAL PHARMACOLOGY 26(6):1243-1247 KROGER H; KLEWER M; GRATZ R; DIETRICH A; OCKENFELS H; MIESEL R EXACERBATION OF ACETAMINOPHEN HEPATOTOXICITY BY THALIDOMIDE AND PROTECTION BY NICOTINIC-ACID AMIDE | 1 | 2 |
852 | 4 | 18 | 470 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(2):380-382 MANDERS SM; KOSTMAN JR; MENDEZ L; RUSSIN VL THALIDOMIDE-RESISTANT HIV-ASSOCIATED APHTHAE SUCCESSFULLY TREATED WITH GRANULOCYTE-COLONY-STIMULATING FACTOR | 1 | 7 |
853 | 0 | 0 | 482 1995 NEUROLOGY 45(4):A168-A168 CLAVELOU P; COLAMARINO R; DINCAN M; DEFFOND D; TOURNILHAC M; SOUTEYRAND P THALIDOMIDE-RELATED NEUROPATHY - A PROSPECTIVE, CLINICAL, ELECTROMYOGRAPHIC TRIAL | 1 | 1 |
854 | 0 | 0 | 507 1996 ARTHRITIS AND RHEUMATISM 39(9):1524-1524 Lee S; Klausner J; Oliver S; Kaplan G; McCullagh E Treatment of rheumatoid arthritis (RA) with thalidomide | 1 | 1 |
855 | 3 | 65 | 510 1996 BIOGENIC AMINES 12(4):305-326 Audit CO Specific functions of polyamines: Actin assembly, cytokinesis induction, targets for thalidomide activity, nitrogen sources for marine ecosystems | 1 | 3 |
856 | 2 | 12 | 520 1996 CLINICAL INFECTIOUS DISEASES 23(3):504-505 Levine AM Editorial response - Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 1 | 1 |
857 | 14 | 24 | 524 1996 EUROPEAN JOURNAL OF DERMATOLOGY 6(5):373-376 Charue D; Chauvin E; Duguet C; Revuz J; Bagot M Thalidomide decreases the production of GM-CSF and TNF-alpha in the mixed epidermal cell-lymphocyte reaction | 1 | 2 |
858 | 10 | 43 | 533 1996 INFLAMMATION 20(2):203-215 Kroger H; Miesel R; Dietrich A; Ohde M; Rajnavolgyi E; Ockenfels H Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice | 1 | 12 |
859 | 4 | 5 | 551 1996 NATURE MEDICINE 2(2):132-132 Crawford CL Thalidomide neuropathy | 1 | 1 |
860 | 5 | 25 | 555 1996 NEUROREPORT 7(12):1881-1886 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy | 1 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
861 | 3 | 44 | 573 1997 AMERICAN JOURNAL OF MEDICAL GENETICS 73(3):251-258 Yang QH; Khoury MJ; James LM; Olney RS; Paulozzi LJ; Erickson JD The return of thalidomide: Are birth defects surveillance systems ready? | 1 | 6 |
862 | 0 | 0 | 575 1997 ANNALS OF INTERNAL MEDICINE 127(10):951-952 Vanchieri C Preparing for thalidomide's comeback | 1 | 1 |
863 | 0 | 0 | 584 1997 BRITISH MEDICAL JOURNAL 315(7110):699-699 Rutter T Thalidomide ban to be lifted in the US | 1 | 1 |
864 | 1 | 236 | 596 1997 COLUMBIA LAW REVIEW 97(7):2153-2176 Bernstein A Formed by thalidomide: Mass torts as a false cure for toxic exposure | 1 | 6 |
865 | 15 | 27 | 608 1997 INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19(5):289-296 Pham-Huy C; Galons H; Voisin J; Zhu JR; Righenzi S; Warnet JM; Claude JR; Duc HT In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A | 1 | 1 |
866 | 0 | 0 | 617 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):76-76 Bower M; Howard M; Gracie F; Phillips R; Fife K A phase II study of thalidomide for Kaposi's sarcoma: Activity and correlation with KSHV DNA load | 1 | 2 |
867 | 0 | 1 | 630 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
868 | 6 | 16 | 632 1997 LEPROSY REVIEW 68(1):61-66 Powell RJ; GardnerMedwin JMM Guideline for the clinical use and dispensing of thalidomide (Reprinted from the Postgraduate Medical Journal, vol 70, pg 901-904, 1994) | 1 | 3 |
869 | 0 | 0 | 640 1997 NATURE MEDICINE 3(1):8-8 Cimons M Thalidomide resurfaces for FDA consideration | 1 | 1 |
870 | 3 | 3 | 645 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1086-1087 Birnkrant D Thalidomide for aphthous ulcers in HIV infection | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
871 | 0 | 2 | 649 1997 SCIENTIST 11(3):1-& Brown KS New uses for thalidomide yielding valuable lessons | 1 | 4 |
872 | 0 | 0 | 659 1998 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 55(17):1746-+ Kepple SR Thalidomide approval brings tight restrictions on access | 1 | 1 |
873 | 0 | 0 | 669 1998 ASM NEWS 64(10):557-558 Fox JL Thalidomide approved for treating leprosy | 1 | 1 |
874 | 2 | 3 | 685 1998 BRITISH MEDICAL JOURNAL 316(7125):149-149 Smithells D Dominant gene probably caused some of defects ascribed to thalidomide | 1 | 1 |
875 | 0 | 0 | 687 1998 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
876 | 5 | 14 | 705 1998 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 66(1):61-65 Moreira AL; Kaplan G; Villahermosa LG; Fajardo TJ; Abalos RM; Cellona RV; Balagon MVF; Tan EV; Walsh GP Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL | 1 | 9 |
877 | 0 | 0 | 728 1998 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
878 | 11 | 23 | 752 1999 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
879 | 0 | 0 | 756 1999 ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
880 | 48 | 79 | 761 1999 BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
881 | 5 | 12 | 811 1999 GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
882 | 2 | 29 | 815 1999 INFLAMMATION 23(6):495-505 Gallily R; Kipper-Galperin M; Brenner T Mycoplasma fermentans-induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10 | 1 | 4 |
883 | 6 | 10 | 816 1999 INTERNATIONAL JOURNAL OF DERMATOLOGY 38(1):76-77 Pizarro A; Garcia-Tobaruela A; Herranz P; Pinilla J Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution | 1 | 1 |
884 | 12 | 27 | 821 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
885 | 1 | 2 | 838 1999 LANCET 353(9149):324-324 Levy R Thalidomide in toxic epidermal necrolysis | 1 | 2 |
886 | 0 | 0 | 841 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
887 | 3 | 5 | 889 2000 ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
888 | 12 | 33 | 961 2000 CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
889 | 0 | 0 | 970 2000 DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
890 | 0 | 0 | 980 2000 GASTROENTEROLOGY 118(4):A582-A582 Kam LY; Vasiliauskas EA; Abreu MT; Hassard PV; Zeldis J; Targan SR Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). | 1 | 6 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
891 | 3 | 20 | 989 2000 INFLAMMATION 24(4):347-356 Lindsay L; Oliver SJ; Freeman SL; Josien R; Krauss A; Kaplan G Modulation of hyperoxia-induced TNF-alpha expression in the newborn rat lung by thalidomide and dexamethasone | 1 | 5 |
892 | 2 | 2 | 990 2000 INFLAMMATORY BOWEL DISEASES 6(2):152-153 Katz JA Thalidomide for Crohn's disease: High dose, low dose, or "no doze" at all? Comment | 1 | 1 |
893 | 17 | 19 | 998 2000 JOINT BONE SPINE 67(4):259-261 Wendling D; Toussirot E; Michel F Thalidomide: a comeback? | 1 | 4 |
894 | 1 | 5 | 1006 2000 JOURNAL OF CLINICAL ONCOLOGY 18(19):3453-3453 Cohen MH Thalidomide in the treatment of high-grade gliomas | 1 | 3 |
895 | 12 | 41 | 1013 2000 JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
896 | 15 | 19 | 1018 2000 LEPROSY REVIEW 71:S117-S120 Kaplan G Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions | 1 | 2 |
897 | 4 | 10 | 1024 2000 MEDICINA-BUENOS AIRES 60:61-65 Politi PM Thalidomide. Clinical trials in cancer. | 1 | 1 |
898 | 13 | 22 | 1056 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(5):301-311 Teo S; Morgan M; Stirling D; Thomas S Assessment of the in vitro and in vivo genotoxicity of Thalomid (R) (Thalidomide) | 1 | 1 |
899 | 1 | 33 | 1089 2001 BIOMEDICAL CHROMATOGRAPHY 15(3):202-206 Duval R; Leveque H; Prigent Y; Aboul-Enein HY Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases | 1 | 4 |
900 | 24 | 32 | 1149 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |